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Abstract
Background: The mechanism of aggressive character of ovarian cancer and unsuccessful treatment of women with
this deadly disease has been recently explained by the theory of cancer stem cells (CSCs). It has been reported that
ovarian carcinogenesis and progression of disease is associated with epithelial-mesenchymal transition (EMT). EMT, a
physiological cell process during embryonic development and later in life during regeneration, could, when
induced in pathological condition, generate CSCs-like cells. Until now EMT in the ovarian tissue has been mainly
studied in cell cultures in vitro. The aim of this study was to focus on in situ morphological changes in the ovarian
surface epithelium of tumor tissue in women with epithelial ovarian cancer after we applied the antibodies for
markers of EMT vimentin and pluripotency-related markers NANOG, SOX2 and SSEA-4.
Methods: We analyzed ovarian tissue sections of 20 women with high grade serous ovarian carcinoma. After eosin
and hematoxylin staining, used in standard practice, immunohistochemistry was performed for vimentin and
markers of pluripotency: NANOG, SSEA-4 and SOX2. We focused on the ovarian surface epithelium in order to
observe morphological changes in tumor tissue.
Results: Among epithelial cells of the ovarian surface epithelium in women with serous ovarian carcinoma we
observed a population of small NANOG-positive cells with diameters of up to 5 μm and nuclei, which filled almost
the entire cell volumes. These small NANOG-positive cells were in some cases concentrated in the regions with
morphologically changed epithelial cells. In these regions, a population of bigger round cells with diameters of
10–15 μm with large nuclei, and positively stained for vimentin, NANOG and other markers of pluripotnecy, were
released from the surface epithelium. These cells are proposed as CSCs, and possibly originate from small stem cells
among epithelial cells. They formed typical cell clusters, invaded the tissue by changing their round shape into a
mesenchymal-like phenotype, and contributed to the manifestation of ovarian cancer.
Conclusions: Our findings show morphological changes in the ovarian surface epithelium in tumor slides of high
grade serous ovarian carcinoma and provide a new population of putative CSCs.
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Background
Ovarian cancer is the second most common
gynecological cancer and the leading cause of death
among all gynecological tumors; the incidence in our
country is 16 per 100,000 females [1]. Approximately
90% of ovarian cancers belong to the group of epithelial
ovarian cancers. The majority, 75% of epithelial ovarian
cancers, are of the serous histologic type. Due to an in-
sufficient screening program for ovarian cancer and a
lack of early specific symptoms, it is difficult to make an
early diagnosis [2]. Consequently, the majority of
patients with ovarian cancer (77.8%) are at the advanced
stage, with metastatic sites disseminated widely within
the peritoneal cavity [1], whereby the time for successful
(complete cytoreductive) surgery has already been
missed. Although the majority of these patients respond
well to standard chemotherapy, achieving remission of
the disease, unfortunately, in over 70% of patients the
tumor relapses in time, resulting in a less than 30%
5-year survival rate [1].
Despite intensive research on ovarian cancer, its mani-
festation is still poorly understood. The mechanism of
the aggressive character of ovarian cancer has recently
been explained by the theory of cancer stem cells (CSC).
CSCs maintain their undifferentiated state and the ability
of self-renewal on one hand and have the ability of dif-
ferentiation, invasion and metastases on the other hand.
Until now, the phenotype and molecular status of popu-
lation of ovarian cancer tumor-initiating stem cells have
not been defined. Even more, the CSC phenotype may
not be uniform among different cancer types and sub-
types or even in tumors of the same histological types or
subtypes [3]. Heterogeneity within tumor cells may lead
to a different course of disease, a different response to
treatment, and drug resistance [4].
Nanog homeobox (NANOG) is a transcription factor,
which, along with transcription factors octamer-binding
protein 4 (OCT4) and SRY-box 2 (SOX2), plays a key
role in the maintenance of pluripotency and self-renewal
in undifferentiated embryonic stem cells (ESCs) [5–9].
The surface antigen SSEA-4 (stage-specific embryonic
antigen 4) is another pluripotent stem cell marker. Its
expression was found in the epithelial ovarian cancer [10].
NANOG has also been detected in different types of tu-
mors, including the epithelial ovarian cancer [9, 11–13].
Even more, the overexpression of NANOG in the epithe-
lial ovarian cancer was associated with a high grade tumor,
advanced clinical stage of disease [13–15], resistance to
chemotherapy [14], and shorter patient survival rate
[14, 15]. The most recent discoveries have also showed
that NANOG regulates the epithelial-mesenchymal
transition (EMT) and chemoresistance through activa-
tion of the signal transducer and activator of transcrip-
tion 3 (STAT3) pathway [16].
The association of EMT with ovarian carcinogenesis and
progression was also reported by other studies [17–19].
EMT is a physiological cell reprogramming event utilized
in tissue remodeling during the embryonic development
and is activated in normal adult tissues during regeneration.
EMT is defined as the loss of epithelial traits by the former
epithelial cells with acquisition of mesenchymal characteris-
tics, such as invasive motility and the presence of vimentin
and myosin [20]. During EMT unique characteristics of
certain mesenchymal cells are acquired, including epithelial
cell polarity, intracellular adhesion and loss of specific cell
surface markers. Due to cytoskeletal remodeling, these cells
subsequently obtain a mesenchymal-like phenotype. The
major molecular characteristics of EMT are the downregu-
lation of epithelial cell markers, E-cadherin and ß-catenin,
and upregulation of the markers of mesenchymal pheno-
type, vimentin, fibronectin and N-cadherin. Recent findings
suggest that EMT, induced in pathological condition, could
generate ovarian CSCs-like cells [21]. EMT in epithelial
tumor cells increases their invasive capacity and enhances
their degree of malignancy [22, 23]. EMT is also considered
a key step in CSC metastases [24]. During EMT, carcinoma
cells lose their epithelial characteristics and acquire
mesenchymal properties that promote extracellular matrix
invasion and distant metastases. Several molecular mecha-
nisms are involved in this process, like down-regulation of
E-cadherin, cytokeratins, zona occludens 1 (ZO-1),
claudins, occludin, laminin-1, entactin, mucin 1 (MUC-1),
the microRNA 200 family, and acquisition of the transcrip-
tion factors Snail 1, Snail 2, Twist, Zeb1 and Zeb2/SIP1 as
well as N-cadherin, fibronectin, vimentin, and others [25,
26]. The major cytoskeletal component of mesenchymal
cells is vimentin, which is usually used as a marker of
mesenchymally-derived cells or cells undergoing an EMT
during metastatic progression, and is related to primary
(intrinsic) resistance or poor response to chemotherapy and
metastasis promotion [27, 28]. Tumor cells undergoing
EMT acquire the capacity to disarm the body's antitumor
defense, resist apoptosis and anticancer drugs [28]. Trans-
formed tumor cells disseminate throughout the organism,
and act as a reservoir that refills and expands the tumor cell
population [29]. As EMT represents a key event in cancer
manifestation and progression, it is becoming a promising
target for anticancer therapy [29, 30].
Until now, EMT has been studied mainly in normal
ovarian cell cultures and ovarian tumor cell cultures in
vitro, but rarely in situ on tumor tissue. The aim of this
study was to apply the antibodies for marker of EMT
vimentin and markers of pluripotency NANOG, SOX2
and SSEA-4 to ovarian tumor sections of women with
epithelial cancer, and focus on morphological changes in
the ovarian surface epithelium. We found a popula-
tion of round cells forming and releasing from the
ovarian surface epithelium that were vimentin and
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NANOG-positive. A similar population of cells was also
identified when SOX2 and SSEA-4 markers of pluripo-
tency were applied. We suggest these cells to be involved
in EMT and manifestation of ovarian cancer. These cells
need to be further researched.
Methods
We analyzed ovarian tumor samples of 20 women with
high-grade serous ovarian carcinoma. Patients were surgi-
cally treated in the Department of Gynecology and
Obstetrics, University Medical Centre Ljubljana, Slovenia,
and tumor samples were collected at the Histopathology
Unit to carry out the histopathological diagnosis and were
then included in our study. Tumor samples were collected
before the patients were treated with chemotherapy. All
tumor samples were reviewed by a single pathologist.
Ovarian tissue sections were stained by hematoxylin and
eosin (HE), common in the daily medical practice, which
resulted in blue-stained cell nuclei. Additionally, immuno-
histochemistry (IHC) was used for analyzing the marker
of EMT vimentin, and pluripotency-related marker
NANOG to identify potential stem cells expressing this
marker and to analyze their localization in the ovarian
surface epithelium. In three women with high grade
serous ovarian carcinoma, the ovarian sections were fur-
ther stained for pluripotency-related markers SSEA-4 and
SOX2. In our study, we focused particularly on cells in the
ovarian surface epithelium that were expressing vimentin
and a degree of pluripotency.
Immunohistochemistry for vimentin
IHC analysis for vimentin was performed on tissue micro-
array. 3-5 μm sections of tumor tissue were cut from the
same multitumor block as in the case of NANOG IHC
analysis. The 3-5 μm-thick paraffin sections were placed
on silane-coated slides (Menzel-Glaser Superfrost) and
dried in a dryer at a temperature of 60 °C for one hour.
IHC staining was performed by an automatic slide stainer
(Ventana BenchMark GX). After deparaffinization antigen
retrieval (HIER) took place at pH 7-8 for 48 min with re-
agent CC1 Ventana. Slides were then incubated with a
monoclonal mouse anti-vimentin antibody, clone V9,
DakoCytomation, at dilution 1: 300 for 30 min at room
temperature. The antigen detection was performed with
the Ventana OptiView Kit. The removal of the primary
antibody served as a negative control. The stained ovarian
sections were monitored under light, inverted, and fluor-
escence microscope. The cells were supposed to be
positive if they featured a brown stain.
Immunohistochemistry for NANOG
IHC analysis was performed on a tissue microarray
(TMA) of tumor samples of serous ovarian carcinoma.
After evaluation of HE stained sections of the ovarian
tumor, the biopsy of representative areas of the tumor tis-
sue was performed with a 2 mm core needle. The biopsy
specimens were then transferred to multitumor paraffin
blocks. 3-5 μm sections were consecutively cut from the
multitumor block. The 3-5 μm thick paraffin sections
were then placed on silane-coated slides (Menzel-Glaser
Superfrost) and were dried for one hour in a dryer at 60 °
C. IHC staining was performed by an automatic slide
stainer (Ventana BenchMark GX). After deparaffinization,
the antigen retrieval was performed. Antigen retrieval
(HIER) was performed with a CC1 Ventana reagent at
pH 7-8 for 48 min. The primary antibody was then
applied. Rabbit anti-human NANOG monoclonal anti-
body (ab109250, Abcam Cambridge, MA, USA) was used
as the primary antibody at a dilution rate of 1:25. Incuba-
tion with NANOG antibody lasted for 30 min at 37 °C.
The antigen detection was performed with the Ventana
OptiView Kit. The removal of the primary antibody served
as a negative control. The stained slides were observed
under microscope. The positive reaction of the NANOG
protein was visible as yellow-brown staining of the nuclei
of cells of the ovarian serous carcinoma.
Immunohistochemistry for SSEA-4 and SOX2
The paraffin embedded ovarian tissue was cut into
4 μm-thick sections which were then placed on silane-
coated slides and dried overnight at 37 °C. The next
morning the sections were deparaffinised and rehydrated
through an ethanol series. Antigen retrieval was
performed in Target Retrieval Solution. The sections
were boiled in Target Retrieval Solution in a microwave
oven (Dako) at low power for 10 min. After cooling
down, the sections were rinsed with phosphate buffered
saline (PBS). When intracellular antigen was observed,
the sections were permeabilized with 0.3% Triton X-100
for 10 min and then rinsed with PBS. Unspecific binding
sites were blocked with 10% fetal bovine serum. The tis-
sue sections were then incubated for 2 h in the mouse
anti-SSEA-4 fluorescein isothiocynate (FITC)-conjugated
antibodies at a dilution rate of 1:200 or mouse anti-
SOX2 phycoerythrin (PE)-conjugated antibodies at a di-
lution rate of 1:100 (both BD Biosciences). The primary
antibody was removed for negative control. After rinsing
the tissue sections with PBS, the slides were mounted
with the Vectashield mounting medium with 4',6-diami-
dino-2-phenylindole (DAPI) (VectorLaboratories). The
stained slides were observed under a fluorescent micro-
scope. After DAPI staining, the cell nuclei were stained
blue. Moreover, the SSEA-4-positive cells expressed
surface green fluorescence and SOX2-positive cells
expressed nuclear red fluorescence. We focused on
SSEA-4 surface green fluorescence staining and SOX2-
nuclei red fluorescence staining, matching DAPI blue
nuclei staining.
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The stained slides were monitored under a micro-
scope. Light microscope (LM) was used at magnifica-
tions up to 1000-times, and in order to better elucidate
the potential stem cells an inverted microscope was used
at magnifications up to 200-times.
Results
Vimentin-positive round cells releasing from ovarian
surface epithelium
After immunohistochemistry for vimentin we found a
population of round cells being released from the ovarian
surface epithelium (OSE). The majority of these cells had
diameters of 10–15 μm, were slightly positive for vimentin
and were being released from OSE (Fig. 1a, b and
Additional file 1: Figure S1). Their nuclei were clearly vis-
ible due to HE staining and filled almost the entire vol-
umes of these cells, which is a characteristic of stem cells.
Sometimes also the nearby epithelial cells expressed a
weak cytoplasmic expression of vimentin (Fig. 1c, d).
When round cells were separated from the OSE they be-
came strongly positive for vimentin (Fig. 1c, d) and
formed typical cell clusters (Fig. 1e-h), which were embed-
ded by a kind of transparent matrix (Fig. 1e-g). Some of
these round cells still had an elongated cytoplasmic resi-
due, which remains from their releasing from the OSE
(Fig. 1d). In these typical cell clusters, there were also
smaller round cells with diameters of around 5 μm
(Fig. 1e-h), which were, similarly to bigger round cells,
strongly positive for vimentin; the nuclei filled almost the
entire volumes of these small cells. Both bigger and small
round cells were completely brown-stained for vimentin
(Fig. 1). In some cases the nearby epithelial cells also
expressed a weak cytoplasmic expression of vimentin
(Fig. 1c, d) but they mostly didn’t.
Proliferation of vimentin-positive cells
When released from the OSE, the round vimentin-
positive cells were intensely proliferating (Fig. 2). In
some places these cells were proliferating also inside the
tissue. The population of proliferating cells was com-
posed of vimentin-positive cells of different diameters
(Fig. 2a-d) and in the majority of them the nuclei filled
almost the entire cell volumes. In Fig. 2e-h we can see
that the proliferating cells included small round cells
with diameters around 5 μm, which expressed a cyto-
plasmic positivity for vimentin; the nuclei filled almost
the entire cell volume of these cells and a thin ring of
cytoplasm was positively stained for vimentin. These
small cells included growing cells and also bigger round
cells with diameters of 10–15 μm, which were strongly
positively-stained for vimentin and were quite similar to
cells released from the OSE (Fig. 2e-h). It is not ex-
cluded that small round cells grew into bigger vimentin-
positive cells, which also formed clusters (Fig. 2g, h).
Vimentin-positive cells invaded the ovarian tissue
In several places of ovarian sections it was possible to
see very similar clusters of round vimentin-positive cells
with diameters of 10–15 μm much like following the re-
lease from OSE, which were invading the ovarian tissue
by changing their round shape into mesenchymal-like
phenotype with protrusions and elongation (Fig. 3).
Moreover, after establishing the mesenchymal-like
phenotype, they remained positive for vimentin. The
round vimentin-positive cells were accumulated and
proliferating at the ovarian tissue surface on several
occasions and were invading inside the tissue by making
their protrusions and elongation, which can be seen in
Fig. 3a-f. These cells remained vimentin positive even
after elongation (Fig. 3h).
Vimentin-positive cells involved in the spread of ovarian
cancer
In Fig. 4 and Additional file 2: Figure S2 we can see the
spread of vimentin-positive cancer tissue in ovarian sec-
tions of women with serous ovarian cancer: earlier spread
(Fig. 4a-d and Additional file 2: Figure S2a-d) and later
spread (Fig. 4e-h and Additional file 2: Figure S2e-h) of
cancer tissue which was positively stained for vimen-
tin. If we look more closely at the pictures, we can
see that the spread of cancer tissue was accompanied
by clusters of round vimentin-positive cells with diameters
of 10–15 μm, which were changing their round shape
into the mesenchymal-like phenotype with protrusions
and elongation and were possibly involved in the
spread of cancer.
Change of epithelial cells: expression of vimentin
In some places of the ovarian sections where the round
vimentin-positive cells were released from the OSE or
invaded the tissue, the nearby epithelial cells in the OSE
layer showed a change: the cytoplasmic positivity for
vimentin, as can be seen in Fig. 5. The round vimentin
positive cells with diameters of 10–15 μm also appeared
among the epithelial cells and spread in the tissue by
changing their round phenotype into the mesenchymal-
like one (Fig. 5d). Otherwise, the epithelial cells in the
OSE layer did not express the vimentin positivity.
Small NANOG-positive cells in the ovarian surface epithe-
lium of women with ovarian serous carcinoma
Among epithelial cells of the OSE in women with serous
ovarian carcinoma, we observed a population of small
NANOG-positive cells with diameters of up to 5 μm and
nuclei that filled up almost the entire cell volumes, a
characteristic of stem cells (Fig. 6). These cells were
present among the epithelial cells without any special
pattern and were observed by both the light microscope
(Fig. 6a and b) and the inverted microscope (Fig. 6c-f).
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All the cells were positively-stained for marker of pluri-
potency NANOG because of the nuclei, which spread
over whole cell volumes. The NANOG-positivity fits
well with the blue staining after HE staining of these
cells. In Fig. 6b and f we can see that these small
NANOG-positive cells were concentrated in the regions
with morphologically changed epithelial cells.
Bigger round cells with large nuclei positively stained for
NANOG
The small cells among epithelial cells were not the only
population of cells expressing the positive nuclear stain-
ing for NANOG. In sections of ovarian tissue of women
with ovarian serous carcinoma we observed some typical
morphological changes of epithelial cells (Fig. 7). It
Fig. 1 Round vimentin-positive cells (arrows) with diameters of 10–15 μm, which were released from the ovarian surface epithelium (OSE). Round
cells, which were slightly positive for vimentin, expressed big nuclei and were being released from the epithelium (a, b). After release from OSE,
these round cells became strongly positive for vimentin (c, d). Some of them still had some cytoplasmic residual after release and were connected
(d). Typical clusters formed from round cells, which released from OSE and were positively-stained for vimentin and embedded by a kind of
matrix (e–h). (Inverted microscope: a–c, e–h, magnifications 100x and 200x; light microscope: d, magnification: 400x) Legend: brown-vimentin positivity
and blue-nuclei after HE staining. Red Bar: 10 μm for a-c and 100 μm for d–h
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looked like the epithelial cells were dividing and some
round cells sized just above 10–15 μm were separating
and releasing from the surface epithelium (Fig. 7a-d).
These separated round cells had large nuclei filling al-
most the whole cell volumes with minimal cytoplasm
around them, which is characteristic of stem cells and
resembled the round vimentin-positive cells described
above. In addition, the separated round cells showed the
positive nuclear staining for NANOG, which matched
well with the blue HE staining, while the “normal” epi-
thelial cells did not show any positivity for NANOG
(Fig. 7a-d). After separation from the surface the epithe-
lium round cells proliferated and formed typical cell clus-
ters (Fig. 7e, f ). In these typical cell clusters some of
NANOG-positive round cells stayed connected with cyto-
plasmic bridges (Fig. 7e, f ). Interestingly, the presence of
such cells was not observed in the ovarian sections of
healthy women. We suggest that these cells expressing
Fig. 2 Proliferation of vimentin-positive round cells, which were released from the ovarian surface epithelium. The majority of cells expressed
diameters of 10–15 μm (a–d). However, there were some smaller cells among them that expressed diameters of around 5 μm (e–h); these smaller
cells expressed cytoplasmic positivity for vimentin. Among these smaller cells were bigger vimentin-positive cells (arrows), which formed clusters
and possibly originate from smaller cells (e–h). (Inverted microscope: a–d, magnifications 100x and 200x; light microscope: e–h, magnification
400x). Legend: brown-vimentin positivity and blue-nuclei after HE staining. Red Bar: 10 μm for b–d and 100 μm for a, e–h
Kenda Suster et al. Journal of Ovarian Research  (2017) 10:11 Page 6 of 15
NANOG may be related to stemness, and it is not ex-
cluded that, based on their properties, they are involved in
the epithelial-mesenchymal transition in situ.
A similar population of round cells with large nuclei
positively stained for SSEA-4 and SOX2, markers of
pluripotency
Similar morphologic changes of epithelial cells in the
ovarian surface epithelium of women with the ovarian
serous carcinoma were found after staining ovarian
sections for pluripotency-related markers SSEA-4 and
SOX2, using immunofluorescence (Fig. 8). After green
SSEA-4 staining we could clearly see similar round cells
separating from the ovarian surface epithelium, which
showed the surface expression of SSEA-4 (Fig. 8d, e);
these cells resembled the round vimentin in NANOG-
positive cells described above. Round cells had sizes just
above 10–15 μm and large nuclei filling almost entire
cell volumes with minimal cytoplasm around them, as
revealed by DAPI staining (Fig. 8d, f ). In addition,
Fig. 3 Invasion of round vimentin-positive cells with diameters of 10–15 μm deeper into the ovarian tissue. These cells (arrows) were at some
places accumulated at the surface of the tissue and progressed deeper into the tissue by their change into the mesenchymal-like phenotype
(a–c) by producing protrusions (d–g) and elongation (h); after changing their shape, they were still positive for vimentin. (Inverted microscope,
magnifications 100x and 200x). Legend: brown-vimentin positivity and blue-nuclei after HE staining. Red Bar: 10 μm for c, d, and 100 μm for a, b, e–h
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separated round cells formed similar cell clusters
(Fig. 8g-i). Some comparable findings were found after
the red SOX2 staining (Fig. 8j-l); round cells showed nu-
clear positivity for SOX-2 and formed comparable cell
clusters. Atrophic (autofluorescent) erythrocytes were
found in vicinity (Fig. 8d, e, j), but they were clearly
distinguished from round cells and did not have the
nuclei as revealed by DAPI staining (Fig. 8 f, l).
Co-action of different types of stem cells in the
manifestation of ovarian cancer
We suggest that the two above mentioned populations
of vimentin and NANOG-positive cells: small cells
among epithelial cells in the ovarian surface epithelium
with diameters of up to 5 μm and bigger round cells
with diameters of 10–15 μm separating from epithelial
cells are putative stem cells (Fig. 9). It is not excluded
Fig. 4 Spreading of cancer tissue by round vimentin-positive cells with diameters of 10–15 μm. In both the region of ovarian sections with early
invasion of vimentin-positive cancer tissue (a–d) and region of later invasion with highly spread cancer tissue (e–h), the round vimentin-positive
cells with diameters of 10–15 μm (arrows) were still present and were changing into the mesenchymal phenotype to possibly spread the cancer
tissue. (Inverted microscope, magnifications 100x and 200x). Legend: brown-vimentin positivity and blue-nuclei after HE staining. Red Bar: 10 μm
for h and 100 μm for a–g
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that small putative stem cells, which are present among
epithelial cells of OSE and concentrate at the morpho-
logical changes of epithelial cells or some other factors,
initiate the epithelial-mesenchymal transition by their
growth and transformation into bigger round cells, posi-
tively stained for vimentin and markers of pluripotency
NANOG, SOX2, and SSEA-4, which release from the
OSE layer, form typical clusters, and invade the ovarian
tissues by changing their round phenotype into
mesenchymal-like phenotype with protrusions and
elongation. We suggest that epithelial-mesenchymal
transition doesn’t mean the transition of epithelial cells
into mesenchymal cells. More likely, this is a transition
of small putative stem cells among epithelial cells into
bigger CSCs which are separated from the epithelium
and further spread the cancer tissue by their change into
the mesenchymal-like phenotype. In spite of that, the
epithelial cells are not excluded from this process and
support it in an unknown way. Perhaps they somehow
embed the small stem cells by their membrane and
cytoplasm and then divide or there is an alternative
substantiation.
Discussion
By applying the pluripotency-related marker NANOG,
we found two different populations of NANOG-positive
cells in sections of ovarian tissue in women with ovarian
serous carcinoma: smaller stem cells among epithelial
cells in the ovarian surface epithelium and bigger round
stem cells releasing from epithelial cells, proliferating
and forming typical cell clusters. Very similar popula-
tions of cells were positive for vimentin, an important
marker of EMT; therefore, we suggest that these two
populations of cells are putative stem cells, which might
be involved in the epithelial-mesenchymal transition and
the manifestation of ovarian cancer.
In general, the origin of CSCs is still poorly under-
stood. There are two generally accepted hypotheses
considering the origin of CSCs: the first one is that there
are CSCs somatic stem cells that have undergone malig-
nant transformation, and the second one is that more
differentiated somatic cells during malignant changes ac-
quire the properties of self-renewal and gain back stems
status. In favour of the first hypothesis is the data that
normal stem cells, due to active self-renewal and long
life span, accumulate genetic mutations that can lead to
malignant transformation and development of CSCs. On
the other hand, it was shown on experimental cancer
models that CSCs are not necessarily derived from
normal stem cells [31].
In our study, we identified small putative stem cells
among epithelial cells of the ovarian surface epithelium
with diameters of up to 5 μm, which expressed the
pluripotency-related marker NANOG. These small puta-
tive stem cells resembled very small embryonic-like stem
cells (VSELs) from some other human adult tissues and
organs such as bone marrow [32] and umbilical cord
blood [33]. The VSELs are proposed to persist as
Fig. 5 Changed epithelial cells in the OSE layer. At some places the round vimentin-positive cells (arrows) were also present in the OSE layer,
which was significantly changed: the epithelial cells expressed cytoplasmic positivity for vimentin (a–c) or the mesenchymal-like cells formed from
them spread among the epithelial cells (d). (Inverted microscope, magnification 100x). Legend: brown-vimentin positivity and blue-nuclei after HE
staining. Red Bar: 100 μm
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dormant in adult human tissues and organs from the
embryonic period of life to regenerate the damaged
tissues and may be involved in the manifestation of
cancer at an inappropriate condition in the body [34].
Very similar cells have already been found in the
ovarian surface epithelium of healthy adult human
ovaries [35–38]. In this study, the immunocytochem-
istry showed that these small VSEL-like stem cells
expressed cytoplasmic positivity for vimentin and
possibly grew into bigger round cells which were
strongly positive for vimentin. In this way, perhaps
the small VSEL-like stem cells activated themselves
and developed into CSCs.
The observation of tumor sections also showed mor-
phological changes of epithelial cells in terms of malig-
nant transformation. We noticed that specific round
cells were being released from OSE in patients with
ovarian serous carcinoma. The separated round cells
were about 10–15 μm in size and had large nuclei, filling
almost the whole cell volume, which is the characteristic
of stem cells. The separating cells were NANOG-
positive, while the OSE was not. Moreover, the similar
population of round cells was also stained positively for
EMT-related marker vimentin and other markers of
pluripotency, such as surface antigen SSEA-4 and
nuclear SOX2, thus further indicating that these cells
may be stem cells involved in EMT. After the separation
of NANOG-positive round cells from the surface epithe-
lium those cells proliferated and formed clusters of iden-
tical cells, which is another characteristic of stem cells.
In cell clusters, some of these round NANOG-positive
cells were still connected by cytoplasmic bridges. Inter-
estingly, cytoplasmic bridges may be found also among
female germ cells – oogonia – which are similarly char-
acterized by the round shape and nuclei filling the whole
cell volumes [39]. EMT induced in pathologic conditions
has already been associated with the generation of CSC-
like cells [21]. We suggest that bigger NANOG-and
vimentin-positive round cells with large nuclei that sepa-
rated from surface epithelium represent putative cancer
stem cells (CSCs) which arise in the EMT process. These
cells proliferated and formed typical cell clusters of
Fig. 6 Small NANOG-positive cells (arrows) among epithelial cells in the OSE of patients with serous ovarian carcinoma observed by both the light
microscope (a, b) at magnification 400x and inverted microscope (c–f) at magnifications 100x and 200x. Legend: yellow to brown-NANOG-positivity and
blue-nuclei after HE staining. Red Bar: 10 μm for d and 100 μm for a–c, f
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identical cells, which might represent the beginning of
tumor formation and invasion. First we thought that
these cells were originating from epithelial cells (e.g., by
their transdifferentiation), but our data show that these
cells possibly originate from small VSEL-like stem cells,
which are present among epithelial cells in the OSE.
The positivity of big round cells – putative cancer stem
cells – for both NANOG and vimentin markers is not a
surprise as it has already been found that the transcription
factor NANOG regulates the epithelial-mesenchymal
transition and chemoresistance through activation of the
STAT3 pathway in epithelial ovarian cancer [16]. The
EMT, a basic process in the morphogenesis of fetal tissues
during embryogenesis and in normal adult tissues during
regeneration, is defined as loss of epithelial traits of former
epithelial cells and acquisition of mesenchymal character-
istics [20]. EMT in epithelial tumor cells increases the cell
invasion capacity and enhances their degree of malignancy
[22, 23]. The characteristic of EMT: increasing cell motil-
ity and invasion [40, 41], metastases and resistance to
drugs [42, 43], are similar to characteristic of the high
grade serous carcinoma: invasion, dissemination, metasta-
ses, resistance to chemotherapy and recurrence of disease.
Based on our data, we suggest that big round cells ex-
pressing vimentin and a degree of pluripotency, released
from OSE and formed typical cell clusters, invaded the tis-
sues and spread the malignancy by change of their round
shape into mesenchymal-like phenotype with protrusions
and elongation.
The EMT process in malignant cells can be triggered
by different signals, some of them expressed by tumor
stroma [44] including transforming growth factor-ß
[45, 46]. Epidermal growth factor receptor signaling
caused ovarian cancer cells to resist cisplatin and to recur
because of the EMT process [47]. The cisplatin-induced
EMT has been found to increase the expression of CSC
Fig. 7 Morphological changes in the ovarian surface epithelium (OSE) of patients with serous ovarian carcinoma: epithelial cells divided and
some round cells (arrows) were separating from the ovarian surface epithelium (a, b). Separated round cells had large nuclei filling almost the
entire cell volumes (c, d). Yellow-brown nuclear staining for NANOG in separated round cells, which nicely conformed to blue HE nuclear staining
(c, d). Separated round cells (circled) were forming cell clusters (e, f). Some round cells stayed connected by cytoplasmic bridges (arrows) and
formed cell clusters (e, f). (Inverted microscope, magnifications 100x and 200x). Legend: yellow to brown-NANOG positivity and blue-nuclei after HE
staining. Red Bar: 10 μm for c, d and 100 μm for a, b, e, f
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markers (NANOG and others) and mesenchymal markers
(N-cadherin, vimentin) and decrease the expression of
epithelial markers (E-cadherin) [48]. Our data show that it
is not excluded that small putative stem cells expressing
NANOG, which were present among epithelial cells,
somehow in some condition trigger the EMT process by
growing into bigger vimentin and NANOG-positive cells
through which CSCs are generated. We observed that
these small NANOG-positive cells were more concen-
trated at places of morphologically changed epithelial cells
and release of typical round cells.
Our data indicate that the process of EMT may be iden-
tified in situ on a tumor tissue and this observation, based
on application of vimentin and stemness/pluripotency re-
lated markers. Maybe this phenomenon could serve as an
important in situ prognostic marker of ovarian cancer in
the future. The knowledge about CSCs and their critical
role not only in cancer development but also in resistance
to drugs and recurrence of disease opens a new possible
way to tumor treatment. CSCs and EMT as the mechan-
ism of development of CSCs can present a new target for
novel drugs for epithelial ovarian cancer treatment. Al-
though many questions regarding CSCs and EMT still re-
main, further research in the field of isolation and in vitro
cultivation of cell cultures as well as in situ observation of
tumor slides may give some additional answers.
Conclusions
The process of EMT has until now been mostly studied
in ovarian cancer cell cultures in vitro. Our findings
show the EMT as a process also appearing in vivo be-
cause we identified it in situ: in tumor sections of the
Fig. 8 Morphological changes (white arrows) in the ovarian surface epithelium (OSE). Round cells with diameters of 10–15 μm were separating
from OSE (a-c). Epithelial cells were dividing and some green stained SSEA-4-positive round cells (e, white arrow) with large blue nuclei after
DAPI staining (f, white arrows) were separating from the ovarian surface epithelium (d–f, white arrows). Separated round cells with large blue
nuclei after DAPI staining (i) were forming cell clusters (g–i, circled) expressing SSEA-4 (h). Atrophic (autofluorescent) erythrocytes (red arrows)
were found in the vicinity (d, e). A similar population of round cells separated from the ovarian surface epithelium (k, white arrow), which form
cell clusters (k, circled) with large blue nuclei after DAPI staining (l), expressing SOX2 marker of pluripotency (k), was also observed. Atrophic
(autofluorescent) erythrocytes (red arrows) are found in the vicinity (j). (Light microscope: a-c, magnification 400x; fluorescence microscope: d–l,
magnifications 400x and 1000x). Legend: green-SSEA4-positivity, red-SOX2-positivity, and blue-nuclei stained by DAPI. Red Bar: 100 μm
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high grade serous ovarian carcinoma. For the first time,
we show a population of putative CSCs, which were
present in situ: round cells with diameters of 10–15 μm
which were positively stained for vimentin, NANOG,
and other markers of pluripotency, were released from
the ovarian surface epithelium, formed typical cell clus-
ters, and were able to invade the tissue by change of
their round shape into mesenchymal-like phenotype
with protrusions and elongation. These cells very pos-
sibly originate from small VSEL-like stem cells, which
were present among epithelial cells in ovarian surface
epithelium and have already been related to ovarian
cancer [49]. Our results better elucidate the CSCs and in-
dicate that further research of CSCs and EMT in situ is
needed in order to better understand the mechanisms of
the ovarian cancer. Extended knowledge about CSCs and
EMT would help in a better diagnosis of ovarian cancer.
CSCs and EMT might also be seen as a possible target for
novel drugs in treatment of epithelial ovarian cancer that
would improve the prognosis of this deadly disease.
Additional files
Additional file 1: Figure S1. Round vimentin-positive cells (arrows) with
diameters of 10–15 μm being released from the ovarian surface epithelium
(OSE). (Light microscope, magnification 400x). Legend: brown-vimentin
positivity, blue-HE stained nuclei. Red bar: 100 μm. (JPG 1069 kb)
Additional file 2: Figure S2. Spreading of cancer tissue by round
vimentin-positive cells with diameters of 10–15 μm. In both the region of
ovarian sections with early invasion of vimentin-positive cancer tissue
(a-d) and region of later invasion with highly spread cancer tissue (e-h),
the round vimentin-positive cells with diameters of 10–15 μm (arrows)
were still present and were changing into the mesenchymal phenotype
to possibly spread the cancer tissue. (Inverted microscope, magnifications
100x and 200x). Legend: brown-vimentin positivity and blue-nuclei after
HE staining. Red Bar: 10 μm for f and 100 μm for a-e, g, h. (JPG 2004 kb)
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Fig. 9 Different populations of vimentin and NANOG-positive (brown)
putative stem cells in ovarian sections of women with serous ovarian
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the layer of epithelial cells and changing into mesenchymal phenotype.
Small stem cells might trigger the epithelial-mesenchymal transition or
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way promote the invasion of ovarian cancer
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